[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure].

Abstract

The purpose of the study was to evaluate hemodynamic and anti-ischemic effects of moexipril in patients with postinfarction left ventricular dysfunction (PL VD) and moderate left ventricular heart failure (NYHA functional class II-III). The subjects of the study were 21 male patients (aged 52.4 +/- 1.1 years) with CHD and PLVD, related to old large-focal anterior myocardial Q-wave infarction. 4-week treatment with ACF-inhibitor moexipril in an average dose of 10.7 +/- 0.4 mg per day clinically improved the patients' condition, which was characterized by 32.2% reduction of stenocardia attack frequency (p < 0.01) and 36.4% decrease in nitroglycerin demand (p < 0.01). Activity tolerance increased by 39.2% (p < 0.001), and echoCG found a 16.5% increase of LV ejection fraction (p < 0.05). Conjunctival biomicroscopy showed that moexipril substantially improved microcirculation (MC); total conjunctival index significantly decreased by 21.7%. The results of the 4-week moexipril administration demonstrate hemodynamic and anti-ischemic effects of the new ACF inhibitor, its positive influence on transcapillary oxygen exchange and MC in patients with PLVD, associated with NYHA functional class II-III heart failure.

• Authors: A T Tepliakov, A V Pchel'nikov, A A Garganeeva, N G Krivonogov
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 83 Issue 1 Pg. 50-3 ( 2005) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Gemodinamicheskaia i antiishemicheskaia éffektivnost' moéksiprila u bol'nykh s postinfarktnoĭ disfunktsieĭ serdtsa i umerenno vyrazhennoĭ levozheludochkovoĭ serdechnoĭ nedostatochnost'iu.
• PMID: 15759492 (Publication Type: Comparative Study, Evaluation Study, Journal Article)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Delayed-Action Preparations
• Tetrahydroisoquinolines
• moexipril

Topics

• Angiotensin-Converting Enzyme Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Coronary Angiography
• Data Interpretation, Statistical
• Delayed-Action Preparations
• Echocardiography
• Electrocardiography
• Exercise Test
• Heart Failure (diagnosis, drug therapy, etiology, physiopathology)
• Hemodynamics
• Humans
• Male
• Microcirculation
• Middle Aged
• Myocardial Infarction (complications)
• Tetrahydroisoquinolines (administration & dosage, adverse effects, therapeutic use)
• Time Factors
• Ventricular Dysfunction, Left (diagnosis, drug therapy, etiology, physiopathology)